BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Geraghty NJ, Watson D, Adhikary SR, Sluyter R. P2X7 receptor in skin biology and diseases. World J Dermatol 2016; 5(2): 72-83 [DOI: 10.5314/wjd.v5.i2.72]
URL: https://www.wjgnet.com/2218-6190/full/v5/i2/72.htm
Number Citing Articles
1
Ronald Sluyter. Protein ReviewsAdvances in Experimental Medicine and Biology 2017; 1051: 17 doi: 10.1007/5584_2017_59
2
Geoffrey Burnstock. Purinergic Signalling: Therapeutic DevelopmentsFrontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00661
3
P.A.F. Pacheco, R.M.S. Galvão, A.F.M. Faria, N.l. Von Ranke, M.S. Rangel, T.M. Ribeiro, M.l. Bello, C.R. Rodrigues, V.F. Ferreira, D.R. da Rocha, R.X. Faria. 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine MacrophagesBioorganic & Medicinal Chemistry 2019; 27(8): 1449 doi: 10.1016/j.bmc.2018.11.036
4
Jessica Gaff, Fitri Octaviana, Connie Jackaman, Peter Kamerman, John Papadimitriou, Silvia Lee, Jenjira Mountford, Patricia Price. Expression in skin biopsies supports genetic evidence linking CAMKK2, P2X7R and P2X4R with HIV-associated sensory neuropathyJournal of NeuroVirology 2023; 29(3): 241 doi: 10.1007/s13365-023-01134-2
5
Geoffrey Burnstock, Gillian E. Knight. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progressionPurinergic Signalling 2018; 14(1): 1 doi: 10.1007/s11302-017-9593-0
6
Mathias Hohl, Felix Götzinger, Simone Jäger, Lea Wagmann, Mert Tokcan, Thomas Tschernig, Jörg Reichrath, Jan M. Federspiel, Peter Boor, Markus R. Meyer, Felix Mahfoud, Michael Böhm. Assessing phototoxic drug properties of hydrochlorothiazide using human skin biopsiesCommunications Biology 2025; 8(1) doi: 10.1038/s42003-025-08064-1
7
N J Geraghty, L Belfiore, D Ly, S R Adhikary, S J Fuller, W Varikatt, M L Sanderson-Smith, V Sluyter, S I Alexander, R Sluyter, D Watson. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host diseaseClinical and Experimental Immunology 2017; 190(1): 79 doi: 10.1111/cei.13005
8
T.B.-D. McEwan, R.A. Sophocleous, P. Cuthbertson, K.J. Mansfield, M.L. Sanderson-Smith, R. Sluyter. Autocrine regulation of wound healing by ATP release and P2Y2 receptor activationLife Sciences 2021; 283: 119850 doi: 10.1016/j.lfs.2021.119850
9
Nicholas J. Geraghty, Kylie J. Mansfield, Stephen J. Fuller, Debbie Watson, Ronald Sluyter. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in micePurinergic Signalling 2017; 13(4): 405 doi: 10.1007/s11302-017-9569-0
10
Aziz Ghaderpour, Ju‐Young Jeong, Youn‐Hee Kim, Yunyun Zou, Kyung‐Sun Park, Eun‐Ji Hong, Young‐Jae Koh, Seung‐Yong Seong. Taurodeoxycholate, a GPCR19 agonist, ameliorates atopic dermatitis in Balb/c miceEuropean Journal of Immunology 2023; 53(5) doi: 10.1002/eji.202250048
11
Ronald Sluyter, Kara L. Vine. N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1βRelease from Murine MacrophagesMediators of Inflammation 2016; 2016: 1 doi: 10.1155/2016/2097219
12
Geoffrey Burnstock. The therapeutic potential of purinergic signallingBiochemical Pharmacology 2018; 151: 157 doi: 10.1016/j.bcp.2017.07.016
13
Ronald Sluyter, Sahil Adriouch, Stephen J. Fuller, Annette Nicke, Reece A. Sophocleous, Debbie Watson. Animal Models for the Investigation of P2X7 ReceptorsInternational Journal of Molecular Sciences 2023; 24(9): 8225 doi: 10.3390/ijms24098225